Promiliad Biopharma was awarded a Phase II STTR award

Promiliad Biopharma was awarded a Phase II STTR award Promiliad Biopharma was awarded a Phase II STTR award for $ 1,496,891 from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to develop a new structural class of antibiotic. This two-year award, “Novel antibacterial agents derived from natural products” will …

Promiliad Biopharma was awarded a Phase II STTR award Read More »